Authors:
Sebbag, I
Rudski, LG
Therrien, J
Hirsch, A
Langleben, D
Citation: I. Sebbag et al., Effect of chronic infusion of Epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension, AM J CARD, 88(9), 2001, pp. 1060
Citation: J. Khoury et D. Langleben, Heparin-like molecules inhibit pulmonary vascular pericyte proliferation in vitro, AM J P-LUNG, 279(2), 2000, pp. L252-L261
Authors:
Langleben, D
Lamoureux, E
Marcotte, F
Schlesinger, R
Dragatakis, L
Crowe, MJ
Langlois, Y
Lemire, F
White, M
Citation: D. Langleben et al., Mitral stenosis obscuring the diagnosis of plexogenic pulmonary arteriopathy and familial pulmonary hypertension, THORAX, 55(3), 2000, pp. 247-248
Authors:
Badesch, DB
Tapson, VF
McGoon, MD
Brundage, BH
Rubin, LJ
Wigley, FM
Rich, S
Barst, RJ
Barrett, PS
Kral, KM
Jobsis, MM
Loyd, JE
Murali, S
Frost, A
Girgis, R
Bourge, RC
Ralph, DD
Elliott, CG
Hill, NS
Langleben, D
Schilz, RJ
McLaughlin, VV
Robbins, IM
Groves, BM
Shapiro, S
Medsger, TA
Gaine, SP
Horn, E
Decker, JC
Knobil, K
Citation: Db. Badesch et al., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease - A randomized, controlled trial, ANN INT MED, 132(6), 2000, pp. 425
Authors:
Langleben, D
Barst, RJ
Badesch, D
Groves, BM
Tapson, VF
Murali, S
Bourge, RC
Ettinger, N
Shalit, E
Clayton, LM
Jobsis, MM
Blackburn, SD
Crow, JW
Stewart, DJ
Long, W
Citation: D. Langleben et al., Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension, CIRCULATION, 99(25), 1999, pp. 3266-3271